IL2 and gastric cancer: Human gastric cancer patient-derived tumour MDSCs suppressed CD4+ T cells ex vivo via IL-10 in response to VIP, leading to reduced IL-2 and IFNγ production and impaired anti-tumour immunity. Inhibiting VIP may represent a viable strategy in targeting the MDSC-IL-10 pathway.